Search

everythinglearnresearchcommunity

for

Search:↓

User discusses hair regrowth using RU58841, minoxidil, and dutasteride. Many users praise the progress and ask about the treatments' effectiveness and side effects.

The user is experiencing side effects like light-headedness and breathlessness from taking Dutasteride, Minoxidil, and Biotin orally. They are considering taking the medication at night to alleviate these symptoms.

Switching from finasteride to dutasteride may be more effective for hair regrowth due to dutasteride's stronger enzyme inhibition, but combining both drugs could enhance results. Some users report better outcomes with dutasteride, while others recommend a gradual transition to prevent potential hair loss.

The post discusses the potential of GT20029 in treating hair loss, questioning if it will replace finasteride or be used alongside existing treatments. A reply indicates that its role is still uncertain.

The user is concerned about using dutasteride for potential hair loss, fearing it might accelerate balding if not effective. They are unsure about the doctor's diagnosis and are considering starting with finasteride instead.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

Dutasteride is considered by some users to be more effective and have fewer side effects than finasteride for hair loss treatment. Users discuss switching from finasteride to dutasteride, with some reporting better results and fewer side effects, while others advise patience with finasteride as results can take time.

PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.

Creating a topical solution combining finasteride and stemoxydine to treat hair loss, and the discussion of whether 15mg of finasteride would be sufficient for 60ml solvent.

HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.

Piroctone olamine is more effective than ketoconazole for increasing hair growth and reducing itching and dandruff. Treatments discussed include Minoxidil, finasteride, and RU58841.

The conversation discusses using pumpkin seed oil, saw palmetto, fo-ti, and astaxanthin for hair loss, with additional use of Nizoral shampoo. Users express skepticism about regrowth and suggest adding a micro derm roller or considering minoxidil and finasteride for better results.

The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.

Dutasteride may inhibit androgen receptors in addition to reducing DHT, potentially explaining its effectiveness over finasteride for hair loss. Concerns about its impact on muscle growth are debated, with some suggesting no significant effects.

Alternating between finasteride and dutasteride is being considered due to cost concerns. The user is worried about losing progress if switching entirely to dutasteride.

The conversation discusses using Bimatoprost for eyebrow regrowth and its potential use on the hairline, with concerns about cost and side effects. Alternatives like topical Minoxidil are mentioned, but the user is worried about aging and acne.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.

PP405 is discussed as a potential hair loss treatment, but its effectiveness and safety are uncertain. Some users express skepticism, while others are hopeful, comparing it to existing treatments like Minoxidil and Finasteride.

The user achieved significant hair regrowth using 0.5mg oral Dutasteride, 2.5mg oral Minoxidil, topical Minoxidil twice daily, Ketoconazole shampoo twice a week, and weekly dermastamping with no side effects. Results were noticeable after 2-3 months, with the best results at 9 months.

A 35-year-old man shares his positive progress in hair regrowth using a daily routine of 5mg oral minoxidil and 0.5mg dutasteride, along with a low light cap, weekly dermarolling, and biweekly ketoconazole shampoo. He reports noticeable improvements without side effects and aims to inspire others considering similar treatments.

The user switched from finasteride to 0.5mg oral dutasteride and added 2.5mg oral minoxidil, along with occasional microneedling, to improve hair regrowth. They reported no side effects and are hopeful for continued progress, especially in the temple area.

Korea launched its first OTC oral hair loss drug, dexpanthenol B5. Users discuss its anti-oxidative and anti-inflammatory effects but note a lack of efficacy studies.

A user seeks a topical hair loss treatment without minoxidil, considering options like finasteride, dutasteride, caffeine, tretinoin, or prostaglandin analogues. Recommendations include products like Strut, Maximus, Zeuss, and custom formulas from compounding pharmacies.

Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.

An 18-year-old is using a high-dose treatment for hair loss, including 2.5 mg dutasteride, topical minoxidil, and injectable GHK-Cu, despite minimal hair loss. Many users suggest reducing the dutasteride dose due to potential side effects and recommend starting with finasteride instead.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Anageninc stopped selling KX-826 (Pyrilutamide) due to a cease and desist letter from Kintor, but this may indicate promising study results and a potential 2024 release.

User starts Nuclear Stack treatment for hair loss, including Dutasteride, Minoxidil, RU58841, Derminator 2, and supplements. Seeks advice on storing and dosing RU58841.

A user is considering switching from finasteride to a combination capsule of dutasteride, oral minoxidil, and biotin for hair loss, but is unsure about the credibility and cost. Other users suggest getting separate prescriptions for better control and cost-effectiveness.